Last reviewed · How we verify

Pregabalin 300mg

University of Missouri-Columbia · FDA-approved active Small molecule Quality 5/100

Pregabalin 300mg is a Small molecule drug developed by University of Missouri-Columbia. It is currently FDA-approved. Also known as: Lyrica, Gabapentinoid, Preemptive analgesia, GLA5PR GLARS-NF1 tablet 300mg.

At a glance

Generic namePregabalin 300mg
Also known asLyrica, Gabapentinoid, Preemptive analgesia, GLA5PR GLARS-NF1 tablet 300mg, P300
SponsorUniversity of Missouri-Columbia
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pregabalin 300mg

What is Pregabalin 300mg?

Pregabalin 300mg is a Small molecule drug developed by University of Missouri-Columbia.

Who makes Pregabalin 300mg?

Pregabalin 300mg is developed and marketed by University of Missouri-Columbia (see full University of Missouri-Columbia pipeline at /company/university-of-missouri-columbia).

Is Pregabalin 300mg also known as anything else?

Pregabalin 300mg is also known as Lyrica, Gabapentinoid, Preemptive analgesia, GLA5PR GLARS-NF1 tablet 300mg, P300.

What development phase is Pregabalin 300mg in?

Pregabalin 300mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing